GGNBP2 Knockout K-562 Cell Line

The GGNBP2 Knockout K-562 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human chronic myelogenous leukemia (CML) K-562 host cell line. This product provides a targeted loss-of-function model for GGNBP2, a transcriptional regulator, within an established leukemic background. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, enabling researchers to interrogate the specific contributions of GGNBP2 to cancer cell biology without altering other genetic components. The cell line is supplied as a stable knockout pool, suitable for functional genomics, signaling pathway dissection, and drug response profiling.

The K-562 cell line is a Philadelphia chromosome-positive, BCR-ABL1-expressing suspension lymphoblast model originally derived from the pleural effusion of a patient in blast crisis of CML. These cells are widely employed to study oncogenic BCR-ABL1 kinase signaling, hematopoietic differentiation, and erythroleukemia biology. Their well-characterized dependency on the BCR-ABL1-driven signaling network makes them an ideal platform for investigating downstream effectors and resistance mechanisms relevant to myeloproliferative disorders and acute myeloid leukemia.

GGNBP2 functions as a transcriptional regulator implicated in hematopoietic proliferation and differentiation, with reported roles in modulating apoptosis and cell cycle progression. Its activity is influenced by upstream signals from the BCR-ABL1 kinase and the STAT5 transcription factor, while downstream effects are mediated through targets such as CDKN1A (p21), BAX, BCL2, MYC, GATA1, and GYPA. GGNBP2 interacts with coregulatory proteins including GGNBP1, ZBTB16 (PLZF), and HDAC1, forming complexes that orchestrate gene expression. Perturbation of GGNBP2 disrupts the transcriptional regulation of key apoptosis and cell cycle genes, potentially through impaired STAT5 and MAPK/ERK pathway activity, thereby altering cellular proliferation and survival in the K-562 context.

In the K-562 host background, loss of GGNBP2 provides a model to elucidate the functional interplay between BCR-ABL1 oncogenic signaling and transcriptional coregulation. As GGNBP2 lies downstream of the BCR-ABL1-STAT5 axis, its knockout allows detailed dissection of how BCR-ABL1 subverts transcriptional programs to promote leukemogenesis. This model is particularly valuable for exploring mechanisms of drug sensitivity and resistance, given the central role of BCR-ABL1 in CML pathogenesis and the clinical relevance of imatinib and other tyrosine kinase inhibitors.

This knockout cell line supports a spectrum of advanced research applications, including functional genomics of GGNBP2 in leukemia, dissection of BCR-ABL1 downstream signaling networks, drug sensitivity profiling with agents such as imatinib, and studies of differentiation therapy. Representative experimental approaches include Western blotting for phospho-STAT5, BAX, and BCL2; RT-qPCR quantification of CDKN1A, MYC, and GATA1 transcripts; flow cytometry for apoptosis (Annexin V) and cell cycle (propidium iodide); MTS proliferation assays; RNA-seq transcriptomics; and ChIP-qPCR to validate GGNBP2 target occupancy. These assays enable rigorous characterization of the knockout phenotype and its impact on hematopoietic transformation. For further information or to request a quote, please contact Ascent Research.